Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
BMC Nephrol. 2022 Apr 18;23(1):153. doi: 10.1186/s12882-022-02791-x.
Steroid pulse (SP) therapy is one of the immunosuppressive therapies for immunoglobulin A nephropathy (IgAN). Although there are various protocols of SP therapy in IgAN, the intermittent SP (ISP) and consecutive SP (CSP) protocols are prevalently performed in clinical settings. However, there is a lack of evidence of comparisons of the effects on IgAN between these two protocols.
A total of 189 patients with IgAN who had received SP therapy were included in this study. They were divided into two groups according to the SP protocols into the intermittent SP (ISP) or consecutive SP (CSP) group as follows: ISP; three-times SP therapy in alternate months, CSP; three-times SP therapy in three consecutive weeks. Kidney function, remission of urinary findings, and side effects of SP therapy were compared between the two groups. The observational period was 12 months after the initiation of SP therapy.
There was no significant difference in kidney function between the two groups during the observational period. The remission rate of proteinuria and hematuria at 12 months also did not significantly differ between the two groups. Furthermore, even after the adjustment of clinical characteristics using propensity score matching, the remission rate of proteinuria and hematuria at 12 months was similar between the two groups. At 2 months, the remission rate of proteinuria was significantly higher in the CSP group than in the ISP group. There were no critical side effects in both groups.
The effects of SP therapy on IgAN were similar between the ISP and CSP group at 12 months although CSP therapy could remit proteinuria faster than ISP therapy.
激素脉冲(SP)疗法是治疗免疫球蛋白 A 肾病(IgAN)的免疫抑制疗法之一。虽然 IgAN 中有多种 SP 治疗方案,但在临床实践中,间歇性 SP(ISP)和连续 SP(CSP)方案更为常见。然而,关于这两种方案对 IgAN 的影响,缺乏比较的证据。
本研究共纳入 189 例接受 SP 治疗的 IgAN 患者。根据 SP 方案将其分为间歇性 SP(ISP)或连续 SP(CSP)组:ISP,隔月 3 次 SP 治疗;CSP,连续 3 周 3 次 SP 治疗。比较两组间肾功能、尿蛋白和血尿缓解情况以及 SP 治疗的副作用。SP 治疗开始后 12 个月为观察期。
观察期间两组肾功能无显著差异。12 个月时蛋白尿和血尿的缓解率在两组间也无显著差异。此外,即使使用倾向评分匹配调整临床特征后,12 个月时蛋白尿和血尿的缓解率在两组间仍相似。2 个月时,CSP 组蛋白尿的缓解率显著高于 ISP 组。两组均无严重副作用。
尽管 CSP 治疗能更快地缓解蛋白尿,但在 12 个月时,ISP 和 CSP 治疗对 IgAN 的疗效相似。